The global veterinary pharmacovigilance market size was valued at USD 702.07 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.49% from 2023 to 2030. Some of the key factors contributing to the market growth include increasing number of veterinary medicinal product approvals, awareness and demand for veterinary pharmacovigilance reporting, need for regulatory compliance, and initiatives by public & private market participants. From January 2022 onwards the EMA’s guidelines on veterinary good pharmacovigilance practices became applicable across Europe. These focus on continuous signal management, maintenance of a pharmacovigilance master file by the marketing authorization holder, and pharmacovigilance inspections by regulators.
The COVID-19 pandemic supported awareness about importance of pharmacovigilance reporting to protect human and animal health. It also catalyzed adoption of and transition to electronic systems and software for reporting by end users such as veterinary CROs, manufacturers etc. Indivirtus for instance, offers a range of veterinary vigilance services to clients such as Alivira Animal Health Limited. However, there exists a wide scope of growth as the market continues to face challenges such as under-reporting of adverse drug events and lack of awareness in developing countries.
One of the key trends includes the adoption of new technologies such as electronic reporting systems and data analytics tools. These technologies allow for more efficient and accurate reporting as well as monitoring of adverse events, and can help to identify potential safety issues before they become more serious. The market is characterized by several emerging trends, including the increasing use of digital technologies such as artificial intelligence and machine learning, the development of pharmacovigilance databases and information systems, and the adoption of proactive pharmacovigilance approaches. These trends are expected to reshape the market and drive its growth in the coming years.
Another factor that drives competition in the veterinary pharmacovigilance market is the increasing regulatory requirements. Regulatory agencies are becoming more stringent in their requirements for veterinary drugs, which has led to an increase in the number of companies that offer regulatory compliance services. This has also led to an increase in competition in the industry as companies strive to differentiate themselves by offering more comprehensive regulatory compliance services.
In addition, the increasing prevalence of chronic diseases in animals, such as cancer and diabetes, has led to a growing demand for specialized drugs and therapies, which in turn has driven the need for more comprehensive pharmacovigilance programs to monitor the safety and efficacy of these treatments.
Anti-infectives segment accounted for the largest share of over 45% of the market in 2022. This was owing to anti-infectives being the most reported products during pharmacovigilance reporting. For example, as per the 2021 Post-MA surveillance report by the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), external parasitics, antimicrobials, internal parasitics, and endectoparasiticides were found to be the most frequently cited product categories in pharmacovigilance reports.
Biologics segment is estimated to grow at the fastest rate of over 14% in the coming years owing to increasing R&D activities and launch of veterinary vaccines. Increasing number of solutions from several market players is expected to contribute to the market growth. Azierta Contract Science Support Consulting offers a range of solutions including Vigialzierta-VET pharmacovigilance software, veterinary QPPV support, pharmacovigilance system support, management, and maintenance, signal detection, and other services to customers from animal health industry.
Software segment dominated the market by solution in 2022 while services segment is projected to grow at the fastest CAGR of about 14% in the near future. Some of the key drivers attributing to the market shares include increasing transition to electronic reporting systems and adoption of pharmacovigilance services to streamline regulatory compliance workflows. Initiatives by companies operating in the market is expected to support the market growth in the coming years. In November 2022, for example Ennov, a key market player, helped a long term Animal Health customer transition its pharmacovigilance operations from a local installation to a SaaS cloud environment.
In May 2022, ArisGlobal a key market player, acquired Signal Analytics Engine- Benefit-Risk Analytic System (BRASS) from Boehringer Ingelheim. The BRASS software is designed for highly regulated environments to support causal analysis of drug safety data. It became a part of ArisGlobal’s LifeSphere platform to support organizations collecting and processing large safety data sets. This helped the company advance its pharmacovigilance and patient safety capabilities.
By type, in-house segment held the highest share of the market in 2022. Contract outsourcing segment on the other hand, is anticipated to grow at a notable rate of over 14%. This is because of the increasing number of animal health companies, increasing product approvals, and outsourcing of pharmacovigilance operations by small & medium animal health companies to save time and costs. Initiatives by market players to enhance their portfolio is another key driver for the market.
In February 2019 for instance, Medfiles expanded its veterinary team with the recruitment of a veterinarian. This enabled the company to offer an even wider range of services. This included consulting, training, national and global pharmacovigilance services, marketing authorization applications and product lifecycle management, as well as a solid veterinary expertise in its services:
Dogs held the largest share of about 50% of the market in 2022 by animal type. Others segment comprising livestock animals and horses is projected to grow at the fastest rate of about 15% from 2023 to 2030. Factors contributing to the growth include rising consumption of animal derived products, increasing pet population and humanization, awareness among animal owners, and increasing importance of regulatory compliance.
As per the 2020 annual bulletin by the EMA, the agency’s EudraVigilance Veterinary received a total of 29,474 companion animal product related adverse event reports in 2019. Of these, dog and cat related reports were found to be most frequent while reports concerning food-producing animals were estimated at 3,228. These reports were received majorly from European countries as well as from the U.S., Brazil, Canada, and 54 other countries.
North America dominated the market by region with a share of about 40% in 2022. One of the key drivers is the growing regulatory environment governing the use of veterinary drugs. The FDA's Center for Veterinary Medicine (CVM) accepts electronic submission of adverse events for veterinary drugs through the Rational Questionnaire (RQ) in the Safety Reporting Portal (SRP) and the Electronic Submissions System (ESS). This continuous monitoring of approved NADAs and ANADAs enables FDA to identify potential problems with the safety and efficacy of approved and marketed new animal drugs as well as potential product/manufacturing problems.
Asia Pacific region is estimated grow at a lucrative CAGR of about 15% over the coming years. This is due to the increasing awareness among animal owners about the importance of animal health and the potential risks associated with the use of veterinary drugs. As pet ownership rates continue to rise in the region, more and more people are seeking high-quality veterinary care for their animals, and are therefore more likely to report any adverse effects or reactions to medications.
The veterinary pharmacovigilance market is a highly competitive industry that involves monitoring the safety and efficacy of veterinary drugs. The industry is driven by the need to ensure that animal health products are safe for consumption by animals and that they do not pose any risks to human health. Competition in the market is expected to remain intense as companies strive to gain a competitive advantage by offering innovative solutions and offering competitive prices. Other strategies deployed by market players include partnerships, expansions, mergers & acquisitions, among others. In February 2021, for example, Cyton and Triveritas merged to become knoell thus creating one animal health team based in the U.S., Europe, U.K., and China. Knoell offers animal health consulting services that include product development and ad hoc services e.g. pharmacovigilance services. Some of the prominent market players in the global veterinary pharmacovigilance market include:
Sarjen Systems Pvt. Ltd.
Pharsafer Associates Limited
Azierta Contract Science Support Consulting
Oy Medfiles Ltd.
Market size value in 2023
USD 0.78 billion
Revenue forecast in 2030
USD 1.89 billion
CAGR of 13.49% from 2023 to 2030
Base year for estimation
Actual estimates/Historical data
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company share, competitive landscape, growth factors, and trends
Solution, product, type, animal type
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Rest of Europe; Japan; China; India; Australia; South Korea; Rest of Asia Pacific; Brazil; Rest of Latin America; South Africa; Saudi Arabia;oRest of MEA
Key companies profiled
ArisGlobal; Accenture; Ennov; Sarjen Systems Pvt. Ltd.; Pharsafer Associates Limited; Knoell; Biologit; Indivirtus; Azierta Contract Science Support Consulting; Oy Medfiles Ltd.
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global veterinary pharmacovigilance market report based on solution, product, type, animal type, and region:
Solution Outlook (Revenue, USD Million, 2018 - 2030)
Product Outlook (Revenue, USD Million, 2018 - 2030)
Type Outlook (Revenue, USD Million, 2018 - 2030)
Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
Other Animal Types
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Middle East & Africa
Rest of MEA
b. The global veterinary pharmacovigilance market size was estimated at USD 702.07 million in 2022 and is expected to reach USD 0.78 billion in 2023.
b. The global veterinary pharmacovigilance market is expected to grow at a compound annual growth rate of 13.49% from 2023 to 2030 to reach USD 1.89 billion by 2030.
b. North America dominated the market by region with a share of about 40% in 2022. One of the key drivers is the growing regulatory environment governing the use of veterinary drugs.
b. Some key players operating in the veterinary pharmacovigilance market include ArisGlobal, Accenture, Ennov, Sarjen Systems Pvt. Ltd., Pharsafer Associates Limited, Knoell, Biologit, Indivirtus, Azierta Contract Science Support Consulting, and Oy Medfiles Ltd.
b. Key factors that are driving the market growth include increasing number of veterinary medicinal product approvals, awareness and demand for veterinary pharmacovigilance reporting, need for regulatory compliance, and initiatives by public & private market participants.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."